Intranasal Immunization with Chitosan-PLGA-rOmp22 Protects Against Multidrug-Resistant Acinetobacter baumannii-Associated Pneumonia.

IF 3.8 2区医学 Q2 CHEMISTRY, MEDICINAL

ACS Infectious Diseases Pub Date : 2025-07-11 Epub Date: 2025-07-01 DOI:10.1021/acsinfecdis.4c01049

Ning Yang, Jianpeng Xue, Runlu Zhou, Yucong He, Yanfeng Zhao, Chenghua Zhu, Mingyue Shao, Nan Gao, Fan Fei, Ganzhu Feng, Xingran Du

{"title":"Intranasal Immunization with Chitosan-PLGA-rOmp22 Protects Against Multidrug-Resistant Acinetobacter baumannii-Associated Pneumonia.","authors":"Ning Yang, Jianpeng Xue, Runlu Zhou, Yucong He, Yanfeng Zhao, Chenghua Zhu, Mingyue Shao, Nan Gao, Fan Fei, Ganzhu Feng, Xingran Du","doi":"10.1021/acsinfecdis.4c01049","DOIUrl":null,"url":null,"abstract":"Acinetobacter baumannii has become a challenge to treat clinically because of the increased number of extensively drug-resistant strains. Vaccination is an effective way to prevent and control A. baumannii infection. In this study, we constructed an A. baumannii nanovaccine Chitosan-PLGA-rOmp22 (CS-PLGA-rOmp22), and evaluated its immunogenicity and protective effects after intranasal immunization. BALB/c mice that received intranasal immunization with the CS-PLGA-rOmp22 nanovaccine displayed long-lasting local mucosal and systemic immunity, and could resist A. baumannii challenge. The CS-PLGA-rOmp22 penetrated the nasal mucosa and promoted the maturation and activation of dendritic cells (DCs) in vitro. Moreover, the immunoprotective effect of intranasal vaccination was comparable to that of subcutaneous immunization. Our findings suggest that this nanovaccine is a potential candidate for preventing A. baumannii infection after mucosal administration.","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":"1880-1892"},"PeriodicalIF":3.8000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.4c01049","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Acinetobacter baumannii has become a challenge to treat clinically because of the increased number of extensively drug-resistant strains. Vaccination is an effective way to prevent and control A. baumannii infection. In this study, we constructed an A. baumannii nanovaccine Chitosan-PLGA-rOmp22 (CS-PLGA-rOmp22), and evaluated its immunogenicity and protective effects after intranasal immunization. BALB/c mice that received intranasal immunization with the CS-PLGA-rOmp22 nanovaccine displayed long-lasting local mucosal and systemic immunity, and could resist A. baumannii challenge. The CS-PLGA-rOmp22 penetrated the nasal mucosa and promoted the maturation and activation of dendritic cells (DCs) in vitro. Moreover, the immunoprotective effect of intranasal vaccination was comparable to that of subcutaneous immunization. Our findings suggest that this nanovaccine is a potential candidate for preventing A. baumannii infection after mucosal administration.

查看原文本刊更多论文

壳聚糖- plga - romp22鼻内免疫可预防多药耐药鲍曼不动杆菌相关肺炎

由于广泛耐药菌株数量的增加，鲍曼不动杆菌已成为临床治疗的挑战。接种疫苗是预防和控制鲍曼不动杆菌感染的有效途径。本研究构建了鲍曼不动杆菌纳米疫苗壳聚糖- plga - romp22 (CS-PLGA-rOmp22)，并对其经鼻免疫后的免疫原性和保护作用进行了评价。经CS-PLGA-rOmp22纳米疫苗鼻内免疫的BALB/c小鼠表现出持久的局部粘膜和全身免疫，并能抵抗鲍曼不动杆菌的攻击。cs - plga - rom22在体外穿透鼻腔粘膜，促进树突状细胞（dc）的成熟和活化。此外，鼻内疫苗接种的免疫保护作用与皮下免疫相当。我们的研究结果表明，这种纳米疫苗是预防粘膜注射后鲍曼不动杆菌感染的潜在候选疫苗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Infectious Diseases CHEMISTRY, MEDICINALINFECTIOUS DISEASES&nb-INFECTIOUS DISEASES

CiteScore

9.70

自引率

3.80%

发文量

213

期刊介绍： ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to: * Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials. * Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets. * Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance. * Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents. * Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota. * Small molecule vaccine adjuvants for infectious disease. * Viral and bacterial biochemistry and molecular biology.